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Abstract
Background: In South and Southeast Asian, the majority of buccal squamous cell carcinoma (BSCC) can arise from
oral submucous fibrosis (OSF). BSCCs develop in OSF that are often not completely resected, causing local relapse.
The aim of our study was to find candidate protein biomarkers to detect OSF and predict prognosis in BSCCs by
quantitative proteomics approaches.
Methods: We compared normal oral mucosa (NBM) and paired biopsies of BSCC and OSF by quantitative
proteomics using isobaric tags for relative and absolute quantification (iTRAQ) to discover proteins with differential
expression. Gene Ontology and KEGG networks were analyzed. The prognostic value of biomarkers was evaluated
in 94 BSCCs accompanied with OSF. Significant associations were assessed by Kaplan-Meier survival and Cox-
proportional hazards analysis.
Results: In total 30 proteins were identified with significantly different expression (false discovery rate < 0.05)
among three tissues. Two consistently upregulated proteins, ANXA4 and FLNA, were validated. The disease-free
survival was negatively associated with the expression of ANXA4 (hazard ratio, 3.4; P = 0.000), FLNA (hazard ratio, 2.1;
P = 0.000) and their combination (hazard ratio, 8.8; P = 0.002) in BSCCs.
Conclusion: The present study indicates that iTRAQ quantitative proteomics analysis for tissues of BSCC and OSF is
a reliable strategy. A significantly up-regulated ANXA4 and FLNA could be not only candidate biomarkers for BSCC
prognosis but also potential targets for its therapy.
Keywords: Oral submucous fibrosis, Buccal squamous cell carcinoma, Quantitative proteomic analysis, Annexin A4,
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Background
Oral submucous fibrosis (OSF) is a chronic and insidious
lesion of oral mucosa which demonstrates particularly
prevalent in some South and Southeast Asian countries
[1, 2]. Its histopathologic feature is characterized by the
inflammatory reaction of juxta-epithelial region followed
by excessive collagen deposition of the lamina propria and
the underlying submucosal layer, with associated epithelial
atrophy [3]. A major clinical symptom of OSF patient is
trismus, a limited ability to open the mouth, which
eventually impairs eating, speaking and dental care [4, 5].
Various epidemiological studies have found that the chew-
ing of areca-nut is the main etiological factor for OSF. [6].
OSF is associated with raised risk for the oral squa-
mous cell carcinoma (OSCC), especially buccal SCC
(BSCC), because buccal mucosa is the most common re-
gion that is stimulated by chewing areca nut [7–9]. The
frequency of OSF canceration has been reported to
range from 3 % to 6 % [10]. The oral precancerous con-
dition defined by WHO is that a generalized pathological
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state of the oral mucosa associated with a significantly
increased risk of cancer, which accords well with OSF
characteristics [8]. Meanwhile, OSF is currently a public
health problem in many countries, especially in some
countries of southeastern Asian [11].
The molecular mechanisms of OSF progression and
oncogenesis remain unclear and may be considered com-
plex events in the deregulated expression of multiple mole-
cules [12]. High-throughput proteomics can perform
analysis to know expression profiles for thousands of pro-
teins and characterize the biologic behaviors of cell simul-
taneously, which can contribute to better understand the
changes of multiple proteins related to the disease progres-
sion and identify diagnostic and prognostic biomarkers.
Different proteomics studies have been successfully en-
gaged in the biomarker discovery of oral cancer. However,
it is still hard to discover unique biomarkers to predict
which oral mucosal disease will progress to OSCC [13, 14].
In the present study, we analyzed normal buccal mu-
cosa (NBM), OSF and BSCC by isobaric tags for relative
and absolute quantification (iTRAQ) system with two-
dimensional liquid chromatography-tandem mass spec-
trometry (2DLC-MS/MS) to find the biomarkers con-
tributed to the diagnosis and prognosis of OSF and
BSCC. iTRAQ can label total peptide, preserve the infor-
mation of post-translational modification and make
quantitative analysis of 4 tissue samples simultaneously
with same experimental conditions [14, 15]. Two novel
protein biomarkers identified in our study may be clinic-
ally useful for BSCC detection arising from OSF, and
evaluate their prognosis values.
Methods
Experimental design and analytical strategy
Briefly, there were three consecutive phases in this
study: first a discovery screen of quantitative proteomics
based on iTRAQ was carried out to identify candidate
biomarkers with the consistently deregulated expressing
levels from NBM to OSF to BSCC, second a protein-
level evaluation of promising biomarkers by western
blotting and immunohistochemistry, and third a valid-
ation of the candidate biomarkers in clinical samples by
a retrospective study. We received ethical approval from
the Xiangya Hospital Human Research Ethics Commit-
tee. All patients included for both the biomarker discov-
ery screen and the retrospective clinical validation study
were diagnosed with a primary BSCC arising from OSF.
Enrolled cases were scheduled for surgical treatment
with informed consent. Meanwhile, all cases had the
habit of areca-quid chewing, and no previous local treat-
ments for oral mucosa. All histological evaluations and
grading were done according to the WHO standard
criteria.
Patients and Tissue Samples
Paired biopsies of BSCC and OSF tissue were collected
from BSCC patient accompanied with OSF lesion simul-
taneously. For every patient, BSCC sample was taken from
the surgical cancer tissue, and matched OSF sample was
from the contralateral buccal mucosa. In addition, un-
matched NBM tissue was procured from healthy volun-
teer without the habit of betel-quid chewing. Each
specimen was divided into three parts: one was for patho-
logic review to confirm the diagnosis, while the remaining
two parts were immediately snap-frozen for quantitative
proteomic and western blotting analysis respectively. If a
paraffin specimen was confirmed by pathologists, it would
be stored for immunohistochemical analysis. Eventually, 6
NBMs, 6 OSFs and 6 BSCCs were enrolled for proteomic
and western blotting analysis. Clinical and histopathologic
details of enrolled cases are listed in Table 1. Ninety-four
formalin-fixed paraffin-embedded BSCC specimens,
which were all removed from primary BSCC patients ac-
companied with OSF between November 2008 to August
2013, were drawn and reconfirmed for the retrospective
clinical validation study. Age, TNM grade, UICC classifi-
cation, OSF and BSCC histological grade, and survival
time were recorded as the clinicopathological data (Add-
itional file 1: Table S1). All enrolled cases had the habit of
areca-quid chewing. All histological evaluations were done
according to the WHO standard criteria.
Reagents and apparatus
iTRAQ™ Reagents Kit was bought from Applied
Biosystems (San Jose, CA, USA). The acetonitrile, formic
acid, acetone, trypsilin, and sodium citrate buffer were
from Sigma-Aldrich (California, CA, USA). The Zorbax
300SB-C18 reversed-phase column (Microm, Auburn,
CA, USA), the Polysulfoethyl column (The Nest Group,
Southborough, MA, USA) and QSTAR XL System (Ap-
plied Biosystem, California, CA, USA) were for 2D LC-
MS/MS. Sep-Pak Vac C18 cartridges was obtained from
Millipore Corporation (Minneapolis, Minnesota, USA).
The rabbit polyclonal antibodies were purchased from
Abcam (London, UK).
Table 1 BSCC patients enrolled for iTRAQ quantitative
proteomic analysis
Case Age Range BSCC
Site
BSCC BSCC OSF
(y) T-stage Differentiation Differentiation
1 30–35 Left T3N1M0 Well Moderate
2 35–40 Left T1N0M0 Well Moderate
3 45–50 Right T3N0M0 Well Early
4 25–30 Left T2N0M0 Well Moderate
5 55–60 Right T2N1M0 Well Advanced
6 45–50 Left T3N2M0 Well Advanced
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Candidate biomarkers discovery by quantitative
proteomic analysis
Protein preparation and iTRAQ labeling
The protein samples were quantitated by the Bradford
method. The iTRAQ labeling was carried on according to
the protocol. Briefly, 200 μg proteins were precipitated at-
20 °C for 60 min. Then they were resuspended in 20 μl
dissolution buffer. After reduction and alkylation, the pep-
tides were labeled with iTRAQ regents for 60 min. Three
iTRAQ regents (115, 116 and 117) were used to label the
peptides of OSF, BSCC and NBM respectively. Sequen-
tially, the samples were mixed together, and desalted by
Sep-Pak Vac C18 cartridges.
2D LC-MS/MS analysis
The mixed labeling peptides were fractionated by strong
cation exchange chromatography (SCX). The mixture
was reconstituted with Buffer A (10 mM KH2PO4 in
25 % acetonitrile, PH 2.6). The mixed peptides were sep-
arated at a 500 μl/min with a gradient of 0-80 % Buffer
B (Buffer B was Buffer A containing 350 mM KCl) in
Buffer A for 1 h. The 215 nm and 280 nm absorbance
was monitored and a total of 12 SCX fractions were got
together. The fractions were dried and resuspended in
50 μl HPLC Buffer A (5 % acetonitrile, 0.1 % formic
acid). Then they were loaded across the Zorbax 300 SB-
C18 reversed-phase column and assessed on a QSTAR
XL System with a 20 AD HPLC system. The elution flow
rate was 0.3 μl/min with gradient 5 %–35 % HPLC Buf-
fer B (98 % acetonitrile, 0.1 % formic acid) for 90 min.
The scans were obtained with m/z ranges of 400–1800
for MS with up to three precursors selected from m/z
100–2000 for MS/MS.
Protein identification
The MS/MS data were searched from the International
Swissprot using the Protein Pilot software 3.0 (Applied
Biosystem, USA). The parameters were as follows: trypsi-
lin as enzyme, methylmethanethiosulphonate of cysteines
residues as modification. Then the Paragon Algorithm
followed by the ProGroup Algorithm (Applied Biosystem,
USA) were used to cancel redundant hits. Parent ion ac-
curacy, fragment ion mass accuracy, tryptic cleavage speci-
ficity, and allowance for missed cleavages were provided
by Protein Pilot. The benchmark for protein identification
was unused Prot-Score >1.3 (95 %) as the threshold. The
relative protein expression was based on the ratio of pep-
tides ions (115:117 or 116:115). We used the fold change
ratio ≤ 0.5 or ≥2 to designate differentially expressed pro-
teins (P < 0.05).
Bioinformatic analysis
Pathway analysis was performed by the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database. Gene Ontology
(GO) database was used to facilitate the biological inter-
pretation of the identified protein in these studies. The dif-
ferentially expressed proteins of GO were divided into 3
categories as follows: biological process (BP), molecular
function (MF) and cellular component (CC).
Validation Studies
Western blotting
30 μg protein was firstly separated with 12 % SDS-PAGE,
then transferred on the polyvinylidene fluoride (PVDF)
membrane. After blocked, filter was incubated by the pri-
mary antibody. The secondary antibody (Santa Cruz Bio-
technology, California, CA) was applied onto the filter at
1:2,000 dilutions. Samples were probed with antiβ-actin
antibody (BD Biosciences, San Jose, CA) as an internal
control. We used ECL system (Amersham, Buckingham-
shire, UK) to visualize bands, and the Bandscan software
(Glyko, Novato, CA) for the analysis of signal intensity.
Immunohistochemical evaluation
Briefly, serial 3 μm thick sections of tissue sample were
mounted on silanized slides. After blocked by 3 %
hydrogen peroxide, sections were incubated by primary
antibodies, then by the biotinylated IgG (Santa Cruz Bio-
technology, CA) for 30 min. Antigen–antibody com-
plexes were dealed with diaminobentzidine (DAB). Then
slides were counterstained by Mayer’s Hematoxylin. The
immunoreactivity of candidate biomarkers were assessed
by counting the number of positive cells. We considered
that ≥10 % positive cells were graded as immunopositive.
For every sample, the result of immunoreactive staining
was evaluated by two observers blinded for the data.
Clinical and prognostic validation in a retrospective case
study
Cohort for the retrospective study
Ninety–four primary BSCCs accompanied with OSFs were
immunohistochemically stained for biomarker candidates.
Follow-up study
All patients undergoing surgery were followed up. The
time to death or recurrence was recorded in detail peri-
odically. Disease free survival time was recorded from
the time of histological diagnosis to the time of the last
follow-up. If a patient died or was found recurrent, sur-
vival time was censored at that time. Overall survival
can not be regarded as a separate parameter, because
among the patients lost to follow up, the death number
could not be ascertained. Only disease free survival of
the patients was recorded.
Statistical Analysis
Statistical analysis of western blotting data was dealed
with Student’s t test. The relationship between the
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expression of proteins and clinicopathological parame-
ters was evaluated by Chi-Square or Fisher’s exact test.
Follow-up studies were evaluated by Kaplan–Meier and
Cox’s Proportional Hazards test. P < 0.05 was regarded
as significant. All statistical analysis was performed by
SPSS 19.0.1 software.
Ethics statement
This study has been approved by the Ethics Board of
Xiangya Hospital, which was also in accordance with the
1975 Helsinki Declaration. All patients had written the




A total of 1998 proteins were identified from 14237 pep-
tides among three tissues, based on the Unused ProtScore
>1.3 (95 %) with at least one peptide above the 95 % confi-
dence. 71.7 % proteins were with at least two peptides. And
56.2 % proteins were identified with three or more
(Additional file 2: Table S2). Compared NBM 117 labeled,
90 proteins were up-regulated and 46 were down-regulated
significantly in OSF 115 labeled. Meanwhile, between BSCC
116 labeled and OSF 115 labeled, 91 differential proteins
were obtained, which contained 51 up-regulated and 40
down-regulated proteins in BSCC. Most importantly, in
total of 30 proteins were identified with significantly differ-
ent expression among three tissue types (Table 2). Among
them, 2 candidate proteins (Annexin A4, ANXA4; Filamin-
A, FLNA) were consistently upregulated, and one protein
(Fibrinogen alpha chain precursor, FGA) was consistently
down-regulated from NBM to OSF to BSCC.
KEGG pathway analysis
Thirty–two signaling pathways among three tissue types
were identified using KEGG database (Fig. 1a). The dif-
ferentially expressed protein clusters could be assigned
into numerous subcategories including the systemic
lupus erythematosus, antigen processing and presenta-
tion, arginine and proline metabolism, focal adhesion,
tyrosine metabolism, and so on. There were cross-talks
among these pathways, as one protein might participate
in several signaling pathways. Alcohol dehydrogenase 4
(ADH4) was involved in the most pathways (9 pathways)
and Systemic lupus erythematosus pathway accounted
for the most differentially expressed proteins (15
proteins) (Additional file 3: Table S3).
GO analysis
These differentially expressed proteins were grouped
into 72 (45.28 %) GO terms based on BP GO terms. The
most enriched BP GO terms included cell redox homeo-
stasis, interspecies interaction between organisms and
oxidation reduction. There were 52 (32.7 %) GO terms
identified by MF classification, and 35 (22.01 %) GO terms
identified by CC classification. The top component for
MF were protein binding, which consisted of 7 proteins.
While the top component for CC were cytoplasm, which
also consisted of 7 proteins (Additional file 4: Table S4).
On the other hand, as shown in Fig. 1b, cellular
process (13.80 %) GO term which belongs to BP
classification accounted for the top GO term, then
the physiological process (13.24 %) and cell part
(8.169 %).





BSCC/OSF (116:115) OSF/NBM (115:117)
ANXA4* IPI00872780.1 4.8305881 2.051162243
MFAP4 IPI00793751.1 0.033419501 5.7543993
GATM IPI00792191.1 3.250873089 0.343557954
CES1 IPI00607801.2 11.16862965 0.108642563
PSME1 IPI00479722.2 3.837071896 0.296483129
KRT19 IPI00479145.2 0.197696999 18.03017807
HIST1H4I IPI00453473.6 0.04786301 2.582260132
VIM IPI00418471.6 0.296483099 2.558585882
FLNA* IPI00333541.6 3.83707315 2.128139019
KRT7 IPI00306959.10 0.246603906 4.285485268
COL1A2 IPI00304962.3 0.343558013 2.167704105
COL1A1 IPI00297646.4 0.27289781 2.884031534
GPD1 IPI00295777.6 0.2511885881 4.055085182
LTB4DH IPI00292657.3 3.630779982 0.405508548
COL6A1 IPI00291136.4 0.366437614 2.83139205
MPO IPI00236556.1 0.205116197 2.466039419
GOT1 IPI00219029.3 0.465586096 8.709635735
ADH4 IPI00218899.5 0.2679167986 5.649369717
GSTM1 IPI00218831.4 0.2051162004 9.549925804
CALM1 IPI00075248.11 0.35318321 13.55189419
CTSG IPI00028064.1 0.251188606 5.105050087
HSP90B1 IPI00027230.3 2.83139205 0.310455948
PDIA3 IPI00025252.1 3.40408206 0.237684026
TF IPI00022463.1 2.754229069 0.322106868
APCS IPI00022391.1 0.110662401 4.830587864
FGA* IPI00021885.1 0.387257606 0.432513833
P4HB IPI00010796.1 3.28095293 0.280543357
PDIA4 IPI00009904.1 3.908409119 0.187068209
EPHX1 IPI00009896.1 3.80189395 0.157036275
HSPA5 IPI00003362.2 2.77971292 0.23120648
*The proteins written with bold words were the same differentially expressed
proteins among three tissue types (from BSCC to OSF to NBM)
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Fig. 1 (See legend on next page.)
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Initial evaluation of candidate biomarkers
ANXA4 and FLNA were selected as the candidate bio-
markers for BSCC arising OSF lesion because the two
showed consistently upregulated from NBM to OSF to
BSCC.
Western blotting
Staining intensities of ANXA4 and FLNA in BSCC were
all significantly higher than OSF and NBM with a con-
secutively upregulated trend from NBM to OSF to BSCC
(P = 0.002 and 0.001, respectively). Representative results
were presented in Fig. 2a.
Immunohistochemistry evaluation
In Fig. 2b, no detectable expression of ANXA4 was
found in NBM, while OSF exhibited brown cytoplasm
staining mainly limited to the spinous epithelial layer,
and sometimes keratinocyte layer together. While in the
BSCC, ANXA4 protein showed intensively staining of
the cytoplasm in cancer cell. The positive expression of
ANXA4 in BSCC was significantly higher than OSF (P =
0.008), while positive ANXA4 of OSF was significantly
higher than NBM (P < 0.0001).
In Fig. 2c, very weak expression of FLNA was shown
in NBM. However, OSF exhibited brown cytoplasm
staining mainly limited to the lower spinous epithelial
layer and basal cell layer. While in the BSCC, FLNA pro-
tein showed intensively staining of the cytoplasm in can-
cer cell. The positive expression of FLNA in BSCC was
significantly higher than OSF (P = 0.004), while positive
FLNA expression in OSF tissues was significantly higher
than NBM tissues (P = 0.01).
Correlation of candidate biomarkers with
clinicopathological parameters
As shown in Table 3, positive ANXA4 and FLNA were
significantly related to T stage (P = 0.017 and P = 0.042,
respectively). Positive ANXA4 showed a forward rela-
tionship with N stage (P = 0.001), while positive FLNA
showed an inverse trend with N stage (P = 0.017). Mean-
while, there was a statistically significant relationship be-
tween positive ANXA4 and tumor stage (P = 0.004),
while no association was found in other parameters.
Association of candidate biomarkers with patient
prognosis
Seventy–three of 94 BSCC patients could be followed
up. Patients were monitored for a period of median
22 months and a maximum of 58 months. Kaplan-Meier
curves revealed that the disease-free survival was associ-
ated significantly with the negative expression of
ANXA4 and FLNA (P = 0.000 and P = 0.000, respect-
ively) in BSCCs in Fig. 3. Hazard ratios calculated by
univariate Cox regression analysis, were 3.4 (95 % confi-
dence interval, 2.2–7.5; P = 0.004) for ANXA4 and 2.1
(95 % confidence interval, 1.7–5.5; P = 0.0036) for FLNA.
ANXA4 and FLNA immunostaining data were com-
bined to form one BSCC group with positive ANXA4
and FLNA expression, and another group with negative
ANXA4 and FLNA. This classification showed an associ-
ation between patients with negative ANXA4 and FLNA
and disease-free survival (P = 0.002) and has a superior
prognostic power with a hazard ratio of 8.8 (95 % confi-
dence interval, 3.0–32.6; P = 0.005).
Discussion
Some previous studies have identified a large number of
differentially expressed biomarkers at the mRNA level
between normal oral mucosa and OSCC or OSF tissues
respectively [16–19]. Meanwhile lots of protein bio-
markers between normal oral mucosa and OSCC have
also been found for long time. However, few studies fo-
cused the differentially expression of protein biomarkers
between NBM and OSF. The present study is the first
comprehensive research on proteins with differential ex-
pression among NBM, OSF and BSCC arising from OSF
by using the iTRAQ shot-gun proteomic approach [20].
In this present study, we used whole tissue rather than
microdissected tissue cells for our proteomics analysis.
We think that whole tissue could have the ability of
reflecting the tumor microenvironment accurately, which
is believed to determine whether cancer can spread
through epithelial-mesenchymal interactions (EMT) [21].
However, the main limitation for whole tissue in proteo-
mics analysis is the cell heterogeneity of different tissues.
By iTRAQ proteomic approach, we identified in total
30 unique proteins from NBM to OSF to BSCC. Among
the deregulated proteins, some were previously reported
to be correlated with the pathogenesis of OSF, such as
KRT19 [16], COL1A2 [22], GSTM1 [23], VIM; [24]
some were not yet observed in OSF but within OSCC,
for instance PSME1 [25], FLNA [26], GOT1 [27],
GSTM1; [28] and some were not reported in any study
on both OSF and OSCC. In addition, a large number of
proteins identified in the previous reports were not
found in our present study. The discordance between
(See figure on previous page.)
Fig. 1 Bioinformatic analysis of differentially expressed proteins. a KEGG pathway analysis of the network relationships between proteins and
related pathways. Red boxes indicate differentially expressed proteins, and yellow circles indicate the related pathways. The depth of red color
shows the p-value which indicates the enrichment of proteins in the pathway. b pie graph of GO mapping for differential expression proteins.
Cellular process GO term accounted for the top GO term, then the physiological process and cell part
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them may be explained partially by the limited dynamic
range of iTRAQ [15]. Moreover, the difference of races
and region distributions, the different processed methods
of areca nut, as well as the different procedure of tissue
collection and management may contribute to the distinc-
tion among various laboratories.
The location, function and regulation of the differen-
tially expressed proteins can be better and easier to
understand by bioinformatics analysis. The results of
bioinformatic analysis showed that most consistently
expressed proteins were randomly regulated proteins
during OSF pathogenesis and carcinogenesis, because
most of them were found in the discrete interaction net-
works. The top 5 GO components showed that the dif-
ferentially expressed proteins in the present study were
located mainly in cytoplasm with the protein binding
function, which contained cell redox homeostasis, inter-
action between organisms, oxidation reduction and
Fig. 2 Initial validation of two candidate biomarkers. a Western blot of ANXA4 and FLNA in the samples of NBM and paired BSCC and OSF, as well as
their corresponding quantifications. b representative immunohistochemical staining for ANXA4. Negative expression of ANXA4 in NBM, brown
cytoplasm staining limited to the spinous epithelial layer of OSF, and intensively staining of the cytoplasm in BSCC cell nest. c representative
immunohistochemical staining for FLNA. Weak expression in NBM samples, brown cytoplasm staining limited to the lower spinous epithelial layer and
basal cell layer of OSF, and intensively staining of the cytoplasm in BSCC cell
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tissue regeneration. The top regulation network in the
study, systemic lupus erythematosus pathway, indicated
that immunological reaction might be the most important
factor during the pathogenesis and carcinogenesis of OSF
lesion, which is in agreement with the conclusions of our
previous study and other research groups [16, 29–31].
Notable proteins in our present study were three con-
sistently deregulated proteins from NBM to OSF to
OSCC, which were related to the mechanisms of the
progression of OSCC arising from OSF. Two consistently
upregulated proteins, ANXA4 and FLNA, were selected
as the candidate biomarkers because we considered that
the progress of OSF pathogenesis and carcinogenesis
could be blocked effectively through interfering their up-
regulated expression. They would be promising targets for
molecular therapy of OSF and OSCC.
The annexins, a multigene family of calcium-dependent
phospholipid-binding proteins, have some special func-
tions include the aggregation of vesicles and regulation of
ion channels as well as roles in the regulation of cell cycle,
cell signal and cell differentiation [32]. Meanwhile, annex-
ins have been found in the processes of several disease, in-
volving in inflammation and several neoplasia [33]. Of all
annexins, ANXA4 was related to the loss of cell adhesion,
and play important roles in apoptosis, carcinogenesis, che-
moresistance, migration and invasion of cancer cells [34].
It binds phospholipids through the Ca-dependent manner
and is located in the nucleus, cytoplasm, or membrane of
cell [35]. ANXA4 was overexpressed in various primary
clinical epithelial tumors, such as renal cancer [34], ovary
cancer [35], gastric cancer [36], colorectal cancer [37],
breast cancer [38], laryngeal carcinoma [38], pancreatic
cancer [38, 39]. Its overexpression could enhanced signifi-
cantly with the tumor stage and poorer prognosis [39],
and be related to promote cell migration in a model tumor
system [37]. These results are correlates with our observa-
tion in the present study that increased ANXA4 expres-
sion is associated with BSCC stage and poor prognosis.
ANXA4 can form protein kinase C complexes. Moreover,
it is found that at least 10 isoforms of protein kinase C
have roles in the progression of cancers, including OSCC
[40]. It could be found association with protein kinase C
that ANXA4 has a vital effect on the BSCC pathogenesis.
All these findings indicate that ANXA4 might have a vital
role in the BSCC progression and migration. Meanwhile,
ANXA4 expression was first identified in OSF tissues,
which further proved the potential carcinogenic capacity
of OSF.
FLNA is a type of actin filament cross-linking protein
that participates in cytoskeletal rearrangement [41]. By
its scaffolding function, FLNA can interact with more
than 90 functionally diverse binding partners to regulate
cellular functions and processes [42, 43]. The FLNA-
deficient cells can not polarize and move because of
their unstable surfaces which can continuously expand
and contract circumferential blebs [44]. The orthogonal
networks of FLNA have the active and reversible
organizational properties, which can protect cell from
various shear stresses [45]. In the present study, we
firstly found that FLNA was positively expressed in OSF.
Obviously, for oral mucosa cells in OSF patients, persist-
ently mechanical shear stress caused by areca-nut chew-
ing could be the key reason for the upregulated FLNA
as a protective reaction of oral mucosa. Mis-regulation
of FLNA plays a critical role in DNA double strand
breaks response for the initiation of tumorigenesis [46].
Meanwhile, because of its ability to control cell mobility,
cell-ECM interactions, cell signaling, and DNA damage
response, FLNA could be regarded as a novel biomarker
for the diagnosis and outcome prediction of cancer.
Table 3 Correlation with clinicopathologic characteristics of the
patients and immunostaining of ANXA4 and FLNA (n = 94)
Cases ANXA4 (+)(%) p value FLNA (+)(%) p value
Gender
Male 83 59(71.1) 0.455 57(68.7) 0.425
Female 11 9(81.8) 5(45.5)
Age
≤40 yr 42 32(76.2) 0.453 28(66.7) 0.896
>40 yr 52 36(69.2) 34(65.4)
T stage
T1 8 3(37.5) 0.017* 2(25) 0.042*
T2 44 29(65.9) 28(63.6)
T3 36 30(83.3) 27(75)
T4 6 6(100) 5(83.3)
N Stage
N0 48 27(56.3) 0.001* 38(79.2) 0.017*
N1 43 38(88.4) 23(53.5)
N2 3 3(100) 1(33.3)
UICC Stage
I 7 2(28.6) 0.004* 4(57.1) 0.696
II 31 19(61.3) 19(61.3)
III 50 41(82) 34(68)
IV 6 6(100) 5(83.3)
Diff.
Well 80 59(73.8) 0.652 55(68.8) 0.180
Moderate 10 6(60) 6(60)
Poor 4 3(75) 1(25)
OSF Stage
Early 27 22(81.5) 0.294 16(59.3) 0.278
Moderated 46 30(65.2) 34(73.9)
Advanced 21 16(76.2) 12(57.1)
* P < 0.05
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Meanwhile, it has been reported that there was the cor-
relation of increased FLNA expression in different stages
of various cancer types and patient outcomes, such as
colorectal cancer [47], pancreatic cancer [48], gliomas
[49], prostate cancer [50] and salivary gland adenoid cys-
tic carcinoma [51]. In the present study, we employed
quantitative proteomic analysis to assess the FLNA ex-
pression and localization. Our data also illustrated that
the expression of FLNA was increased in BSCC, and a
poor survival index for patients with BSCC have high
FLNA levels. So it is conceivable that the FLNA level in
BSCC can be developed as a promising biomarker for
the outcome prediction of BSCC.
Conclusion
Taken together, our proteome analysis has revealed a
number of potential biomarkers among NBM, OSF and
BSCC. Meanwhile, of these, ANXA4 and FLNA seem to
Fig. 3 Kaplan-Meier curves of local disease free survival of BSCC patients accompanied with OSF in relation to ANXA4 staining, FLNA staining,
and the combination of both
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have large prognostic value for patient survival, which
may represent OSF and BSCC biomarkers and potential
targets for therapeutical intervention. To our knowledge,
although ANXA4 and FLNA has been reported on the
carcinogenic roles of some tumors, no studies has been
published on their expression in BSCC arising from
OSF. However, more large-scale, prospective multicenter
trials should be carried out to further elucidate their
value in the clinic, and the roles of two biomarkers in
BSCC development and invasion are in need of further
study.
Additional files
Additional file 1: Table S1. Age, TNM grade, UICC classification, BSCC
histological grade, OSF histological grade, survival status and time, and
the IHC expression of ANXA4 and FLNA were recorded as the
clinicopathological data of 94 cases.
Additional file 1: Table S1. Age, TNM grade, UICC classification, BSCC
histological grade, OSF histological grade, survival status and time, and
the IHC expression of ANXA4 and FLNA were recorded as the
clinicopathological data of 94 cases.
Additional file 2: Table S2. There are four excel files in the supplement
table S2. No. 1 is “total proteins”, which presents all identified proteins
among NBM, OSF and BSCC. No.2 is “DP-(115–117)”, which presents the
differential proteins identified between OSF (115) and NBM (117). Red
proteins mean the upregulated differential proteins in OSF with the
change fold (115:117) > 2, while the blue proteins mean the
downregulated proteins in OSF with the change fold (115:117) < 0.5. No.3 is
“DP-(116–115)”, which presents the differential proteins identified between
BSCC (116) and OSF (115). Red and blue proteins mean the up–or down–
regulated proteins respectively in BSCC. No.4 is “DP-(116–115–117)”, which
presents the differential proteins identified among BSCC (116), OSF (115)
and NBM (117). Red proteins mean consistently upregulated ones, and blue
one was consistently down-regulated from NBM to OSF to BSCC.
(XLS 725 kb)
Additional file 3: Table S3. KEGG pathway analysis was done for 30
differential proteins from BSCC to OSF to NBM. There are 2 excel files in
the supplement table S3. No. 1 is “pathway indexe by Pathway_kegg”,
which presents 32 pathways in total 30 proteins and the pathway of
Systemic lupus erythematosus contains the most proteins. No. 2 is
“pathway indexe by Symbol”, which presents ADH4 contains the most
pathways. (XLS 22 kb)
Additional file 4: Table S4. GO analysis was done for 30 differential
proteins from BSCC to OSF to NBM. There are 3 excel files in the
supplement table S4. No. 1 is “go indexe by GO_molecular_ function”,
which presents that in the molecular function protein binding contains
the most proteins. No. 2 is “go indexe by GO_biological_process”, which
presents that in the biological process cell redox homeostasis contains
the most proteins. No. 3 is “go indexe by GO_cell_component”, which
presents that in the cell component cytoplasm contains the most
proteins. (XLSX 20 kb)
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